NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)

Program leverages NeoGenomics' expertise to provide ovarian cancer patients critical insights to ensure they are getting the right treatmentFT. MYERS, FL / ACCESSWIRE / November 18, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of …